03062021Sat
Last updateFri, 05 Mar 2021 10am
>>

Harvard’s Wyss Institute collaborates with GBS Inc. on the Wyss’ eRapid-based COVID-19 diagnostic to help curb the pandemic

The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard UniversityCombination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications

By Benjamin Boettner

The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute’s eRapid technology with the company’s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.

The research collaboration further cements both parties’ commitment to bringing the electrochemical detection system forward as a diagnostic tool during the pandemic, and follows a licensing agreement coordinated by Harvard’s Office of Technology Development (OTD) in November 2020 that granted The iQ Group Global non-exclusive, term-limited access to the eRapid technology in accordance with the University’s commitment to the COVID-19 Technology Access Framework.

“In this relentless pandemic, a diagnostic platform that can rapidly measure multiple COVID-19-related biomarkers at the pharmacy, doctor’s office or even at home in an affordable way would have enormous advantages, and enable us to understand the pathophysiology of the disease as it develops, persists, and is controlled by vaccination and anti-viral therapies,” said Wyss Founding Director Donald Ingber, M.D., Ph.D. “The point-of-care diagnostic we are striving for will hopefully be able to do all this, and in addition potentially provide immediate insight into where in the disease process patients find themselves.” Ingber also is a lead of the Wyss Institute’s Bioinspired Therapeutics and Diagnostics Platform, and the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.

eRapid was developed by a cross-disciplinary Wyss team led by Ingber and Wyss Senior Staff Scientist Pawan Jolly, Ph.D. as a low-cost, affinity-based electrochemical sensing platform that can simultaneously detect and quantify of a broad range of biomarkers, with high sensitivity and selectivity, from a small volume of complex biological fluids, such as whole blood or saliva. The team had initially applied the technology for detection of sepsis and other life-threatening diseases; however, motivated by the rapidly spreading pandemic, they are also configuring eRapid as a comprehensive COVID-19 biomarker detection technology.

The eRapid technology uses a novel, low-cost, antifouling nanocomposite coating to which SARS-CoV-2-specific ligands may be attached in order to capture viral proteins or RNA, as well as host antibodies and other proteins produced by infected individuals in response to the virus. Upon chemically detecting any one of these virus-specific molecules, the eRapid platform generates an electrical signal that correlates in strength with the levels of target molecules that are detected. The Wyss team has recently dramatically improved the cost-effectiveness of eRapid by developing a graphene-based surface chemistry that further enhances biomarker detection relative to earlier versions of the coating, and dramatically decreases fabrication costs.

“We feel fortunate to be able to benefit from GBS Inc.’s experience with quality control and their insights into requirements from regulatory agencies. This close working relationship will hopefully provide a significant push towards the commercialization of eRapid as a comprehensive COVID-19 biomarker detection system for use in clinical point-of-care applications,” said Jolly, who has helped to pioneer the eRapid technology.

The collaboration aims to further validate the use of the Wyss Institute’s eRapid technology for SARS-CoV-2 detection and to test it in combination with The iQ Group Global’s biosensor platform that has been developed and is commercialized by GBS Inc. The company’s biosensor technology uses a proprietary Organic Thin Film Transistor technology (OTFT), which can significantly enhance electrical signals such as the ones generated by eRapid. Ultimately, this could enable COVID-19-related biomarker signals to be read out in real time in point-of-care smart devices.

“Incorporating the Wyss’ clever antifouling coating into the OTFT biosensor platform technology offers a new diagnostic tool for COVID-19 that can be printed onto plastic strips at a massive scale, ensuring a rapid test for everyone, everywhere,” said Paul Dastoor, Ph.D., inventor of the OFTF biosensor platform, and Professor at the School of Mathematical and Physical Sciences of The University of Newcastle, Australia.

“The Wyss Institute was a natural and complementary fit for this collaborative research, with their track record of electrochemical sensing technology,” said Dr. George Syrmalis, Group Chief Executive Officer of The iQ Group Global. “With multiple vaccines in the process of being approved and distributed, it is clear that there remains an important need for rapid, point-of-care diagnostic solutions to ensure accurate testing as we fight to curb the coronavirus pandemic for people globally.”
www.wyss.harvard.edu

 

comments
  • Latest Post

  • Most Read

  • Twitter

Who's Online

We have 4404 guests and one member online

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.